| Literature DB >> 35291471 |
Amani A AlJohi1, Safanah AlSaeed1.
Abstract
[Purpose] Cancer survivors have functional impairments that adversely affect patients' quality of life (QoL). Acute rehabilitation helps to reduce disability and improves QoL in cancer survivors. This study investigated the potential improvement in mobility levels and QoL of cancer patients during acute inpatient physical therapy (PT) from admission to discharge. [Participants and Methods] This was a cross-sectional study conducted at King Fahad Medical City, Riyadh. Acute inpatient cancer survivors (n=99) were assessed at their admission and discharge. The primary outcome measure was the AM-PAC "6-Clicks" Basic Mobility, Functional Assessment of Cancer Therapy-General (FACT-G7) and the Karnofsky Performance Scale (KPS).Entities:
Keywords: Cancer; Mobility; Quality of life
Year: 2022 PMID: 35291471 PMCID: PMC8918103 DOI: 10.1589/jpts.34.204
Source DB: PubMed Journal: J Phys Ther Sci ISSN: 0915-5287
Fig. 1.Patient recruitment strategy distribution after referral to physical therapy.
CCC: comprehensive cancer center; PT: physical therapy.
Demographic and clinical characteristics of study’s participants
| Continuous variable | Mean ± SD | Median (min, max) | |
| Age (years) | 53.8 ± 15.0 | 57 (16, 88) | |
| Number of PT sessions | 10.7 ± 10.1 | 7 (2, 58) | |
| Categorical variables | n | % | |
| Gender | Male | 23 | 23.2 |
| Female | 76 | 76.8 | |
| Category diagnosis | Breast cancer | 26 | 26.3 |
| Gastrointestinal cancer | 21 | 21.2 | |
| Lymphoma | 14 | 14.1 | |
| Leukaemia | 8 | 8.1 | |
| Gynaecologic cancer | 7 | 7.1 | |
| Othera | 23 | 18.2 | |
| Type of service | Hematology | 26 | 26.3 |
| Oncology | 73 | 73.7 | |
| Discharge | Home | 82 | 82.8 |
| Transferred to other services | 17 | 17.2 | |
| Comorbidities | Spine metastasis | 11 | 11.1 |
| Bone metastasis | 9 | 9.1 | |
| DVT+PE | 6 | 6.1 | |
| Brain metastasis | 6 | 6.1 | |
Sarcoma, neuroendocrine ca, multiple myeloma (MM), mixed, head and neck, genitourinary, lung cancer, brain cancer, and bladder cancer.
Functional outcomes of cancer patients at admission and discharge
| Mean ± SD | Median (min, max) | |
| KPS admission | 52.2 ± 14.7 | 50 (30, 80) |
| KPS at discharge | 57.65 ± 16.8*** | 60 (30, 90) |
| Total mobility at admission (AM-PAC) | 14.57 ± 5 | 14 (6, 24) |
| Total mobility at discharge (AM-PAC) | 16.65 ± 5.6*** | 19 (6, 24) |
| FACT-G7 Total at admission | 13.92 ± 5.4 | 14 (2, 27) |
| FACT-G7 Total at discharge | 17.09 ± 5.8*** | 17 (2, 28) |
Wilcoxon Signed Ranks Test; ***p<0.001.
Fig. 2.Distribution of patients according to the changes in functional assessment tools (KPS, AM-PAC, and FACT-G7).
Comparison of KPS, AM-PAC and FACT-G7 mean and median scores at admission and discharge by discharge destination
| Home (n=82) | Other (n=17) | |||
| Mean ± SD | Median (min, max) | Mean ± SD | Median (min, max) | |
| KPS admission | 54.39 ± 14.3 | 50 (30, 80) | 41.76 ± 12.3 | 40 (30, 60) |
| KPS at discharge | 62.32 ± 14.2*** | 70 (30, 90) | 35.88 ± 9.3 | 30 (30, 60) |
| Total mobility at admission (AM-PAC) | 15.24 ± 4.7 | 16 (7, 24) | 11.29 ± 4.9 | 9 (6, 20) |
| Total mobility at discharge (AM-PAC) | 18.20 ± 4.6*** | 20 (9, 24) | 9.18 ± 3.6 | 8 (6, 18) |
| FACT- G7 (at admission) | 14.16 ± 5.4 | 14 (6, 24) | 12.76 ± 5.2 | 13 (3, 22) |
| FACT- G7 (at discharge) | 17.73 ± 5.6*** | 18 (2, 28) | 14.00 ± 6.0 | 16 (2, 24) |
Wilcoxon Signed Ranks Test; ***p<0.001.
Comparison of KPS, AM-PAC and FACT-G7 mean and median scores at admission and discharge by disease metastasis
| Spine metastasis (n=11) | Bone metastasis (n=9) | ||||
| Mean ± SD | Median (min, max) | Mean ± SD | Median (min, max) | ||
| KPS admission | 45.45 ± 18.0 | 40 (30, 80) | 44.44 ± 16.6 | 40 (30, 80) | |
| KPS at discharge | 54.55 ± 19.1 | 60 (30, 80) | 46.67 ± 18.7 | 40 (30, 80) | |
| 0.793a | |||||
| Total mobility at admission (AM-PAC) | 12.82 ± 6.6 | 9 (6, 23) | 11.67 ± 5.6 | 10 (6, 23) | |
| Total mobility at discharge (AM-PAC) | 15.91 ± 6.2 | 17 (6, 23) | 13.44 ± 6.6 | 12 (6, 23) | |
| FACT-G7 Total at admission | 16.09 ± 4.7 | 17 (6, 24) | 15.33 ± 5.05 | 15 (6, 22) | |
| FACT-G7 total at discharge | 18.00 ± 3.1 | 18 (13, 23) | 17.44 ± 5.3 | 17 (9, 26) | |
| DVT+PE (n=6) | Brain metastasis (n=6) | ||||
| KPS admission | 51.67 ± 11.6 | 50 (40, 70) | 56.67 ± 13.6 | 60 (40, 70) | |
| KPS at discharge | 58.33 ± 16.0 | 65 (30, 70) | 60.00 ± 10.9 | 60 (40, 70) | |
| Mobility at admission (AM-PAC) | 16.0 ± 4.0 | 15.50 (11, 22) | 16.83 ± 5.1 | 18.5 (9, 22) | |
| Mobility at discharge (AM-PAC) | 17.67 ± 6.1 | 19.50 (7, 23) | 18.83 ± 3.4 | 19 (13, 23) | |
| FACT-G7 (at admission) | 13.83 ± 3.7 | 13 (10, 21) | 12.17 ± 3.4 | 13 (6, 16) | |
| FACT-G7 (at discharge) | 14.33 ± 6.5 | 16 (2, 20) | 12.5 ± 3.1 | 13 (8, 17) | |
Wilcoxon Signed Ranks Test.
Results of multiple linear regression model on total AM-PAC score at discharge
| Variable | Coefficient (b) | Std. Error |
| Intercept | 2.05 | 2.80 |
| Total admission AM-PAC score | 0.45** | 0.09 |
| Total admission FACT-G7 score | 0.21 | 0.07 |
| Gender, Male | −1.51** | 0.93 |
| Age | −0.02 | 0.03 |
| Number of sessions | 0.91** | 0.04 |
| Cancer site (Ref. other cancers) | ||
| Breast cancer | 0.70 | 1.14 |
| Gastrointestinal cancer | 2.48 | 1.12 |
| Lymphoma cancer | 4.13 | 1.28 |
| Leukemia cancer | 2.45 | 1.19 |
| Gynecologic cancer | 0.25 | 1.58 |
| Discharge destination, home | 6.05** | 0.96 |
| Comorbidity | ||
| Spine metastasis | −1.19 | 0.25 |
| Bone metastasis | −1.09 | 0.21 |
| DVT+PE | −1.50 | 0.51 |
| Brain metastasis | −0.02 | 0.59 |
R-squared=0.752, adj-R-squared=0.713; F=13.74, **p<0.01.
Results of multiple linear regression model on total FACT-G7 score at discharge
| Variable | Coefficient (b) | Std. Error |
| Intercept | 10.40 | 4.07 |
| Total admission AM-PAC score | 0.24 | 0.14 |
| Total admission FACT-G7 score | 0.52** | 0.11 |
| Gender, Male | −0.43 | 1.33 |
| Age | 0.01 | 0.04 |
| Number of sessions | 0.81** | 0.04 |
| Cancer site (Ref. other cancers) | ||
| Breast cancer | −1.02 | 1.65 |
| Gastrointestinal cancer | −2.27 | 1.63 |
| Lymphoma cancer | 1.16 | 1.86 |
| Leukemia cancer | 2.40 | 2.16 |
| Gynecologic cancer | 0.69 | 2.30 |
| Discharge destination, home | 3.97** | 1.39 |
| Comorbidity | ||
| Spine metastasis | 0.31 | 1.75 |
| Bone metastasis | −0.27 | 1.85 |
| DVT+PE | −1.00 | 2.25 |
| Brain metastasis | −2.57 | 2.31 |
R-squared=0.472, adj-R-squared=0.442; F=4.39, **p<0.01.